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First, the aim of our study, as is stated in the intro-
duction, was to assess the cost-eﬀectiveness of various
antiviral drugs [1]. The “no therapy” strategy was in-
cluded because a considerable number of patients with
chronic hepatitis B have their treatment deferred for dif-
ferent reasons. Secondly, as direct comparisons between
antiviral treatments are not available then indirect com-
parison remains the only approach to evaluate cost-
eﬀectiveness of any anti-HBV therapy. The limitations
of indirect treatment comparisons in cost assessment
are well recognized. For this reason, modeling tech-
niques are especially appropriate and indicated to com-
pare the data from diﬀerent sources [2]. Indeed,
modeling techniques allow extrapolation of short/med-
ium-term results from clinical trials to long-term eﬀec-
tiveness outcomes, which is what we did in our model,
in line with previous studies [3,4]. In addition, the prob-
abilistic sensitivity analysis helps the reader to better
understand eventual diﬀerences between the compared
options even if the primary data, virological response
rates, do not derive from head-to-head studies compar-
ing diﬀerent antiviral options, as occurs in chronic hep-
atitis B treatment. The robustness of our model was
exhaustively tested in the probabilistic analysis, and
the expected variability was analysed within the Monte
Carlo simulation. Finally, the basic cost-eﬀectiveness re-
sults depicted in Figures 1 and 2 of the manuscript [1]
clearly show that a number of treatment options are
dominated by others (in some cases by more than one
option) [1]. Thus, the only incremental cost-eﬀectiveness
ratios (ICERs) to be calculated are those of the more
eﬀective options relative to immediately less eﬀective op-
tions, performing a standard incremental cost-eﬀective-
ness analysis. In our study, ICERs are shown for
tenofovir vs. lamivudine and no treatment (Table 5 of
the manuscript [1]), and the only ICERs omitted are
those of lamivudine vs. no treatment in both HBeAg-po-
sitive and HBeAg-negative patients.
In our opinion, the only real contribution of the letter
by Mantovani and de Portu is when they point out that
lamivudine is a cost-eﬀective option in relation to “no
treatment”. This is a well-known fact that has little cur-
rent relevance, since lamivudine is not a recommended
ﬁrst-line option in the treatment of chronic hepatitis B
infection.
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I read with great interest the review article by Prof.
Liaw published in a recent issue of this journal [1].
The article highlighted the reality and diﬃculties many
patients and clinicians in Asian countries are now facing
in the treatment of chronic hepatitis B. Although the
more recent antiviral agents (entecavir and tenofovir)
have strong antiviral potency and very low risk of drug
resistance, these drugs may not be available to all pa-
tients in need. This is due to the restricted reimburse-q HLYC is an advisory board member of Bristol-Myers Squibb,
oche, Novartis Pharmaceutical, Pharmasset and Schering-Plough.ment criteria in place in diﬀerent countries as well as
the low income of the population in some areas.
In 2008, the gross national income per capita in Hong
Kong was approximately USD 30,380, which was com-
parable to that of Singapore, Japan, Australia and Eur-
ope [1]. Instead of full reimbursement for antiviral
drugs, Hong Kong has very restricted criteria of reim-
bursement. Before July 2008, lamivudine was the only
drug reimbursable to patients with signiﬁcant disease
activity while adefovir could only be reimbursed for pa-
tients with lamivudine resistance and signiﬁcant disease
activity. After July 2008, lamivudine was not reimburs-
able to treat new patients. Instead, entecavir could be
marily as a salvage therapy for lamivudine resistance,
patients who had adefovir started on virological break-
through with normal ALT did not meet the criteria for
reimbursement due to the lack of disease activity. The
ﬁnancial restrictions inevitably delayed the commence-
ment of adefovir for the best treatment outcome [6]. In
a recent report, 14 of the 26 patients with lamivudine
resistance had ALT higher than 2 times ULN when ade-
fovir was started in our clinic, and this was translated to
a suboptimal viral suppression in the long term [7].
I agree with Prof. Liaw that application of the road-
map approach by starting with a cheaper antiviral agent
and switching to other agent(s) if HBV DNA is still
detectable at 24 weeks of treatment should be explored
[1]. In a recent cost-eﬀectiveness analysis in Hong Kong,
the roadmap approach starting with telbivudine or lam-
ivudine and switching to entecavir if HBV DNA sup-
pression is detectable at week 24 may be a cost-
eﬀective alternative to monotherapy with entecavir to
all patients [8]. At present, tenofovir is not registered
for the indication of chronic hepatitis B in Hong Kong
and can only be prescribed after application for oﬀ-label
use. The cost of tenofovir is currently higher than that of
entecavir, but it will be an attractive alternative if its cost
can be lowered as in the case of Europe. To facilitate the
use of the limited resources to treat the large number of
chronic hepatitis B patients in Asia, proper local cost-
eﬀective analysis should be performed before a reim-
bursement policy is reinforced.
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Fig. 1. Number of patients on diﬀerent antiviral treatments during the
audit period. Thirteen patients on adefovir were also on lamivudine or
entecavir as combination therapy. The shaded area indicated patients
who were on self-paid treatment and the clear area indicated patients on
reimbursed treatment from the hospital.
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(ALT) higher than 5 times the upper limit of normal
(ULN) and patients with decompensated liver cirrhosis.
Use of these antiviral drugs outside the listed indications
as well as other antiviral agents (peginterferon, telbivu-
dine, tenofovir) was at the patients’ own expense.
We performed a drug expenditure audit over 4 weeks
between November and December 2008. Four hundred
and forty-four chronic hepatitis B patients attended
the outpatient clinic during the audit period. One hun-
dred and sixty-three (37%) patients had received antivi-
ral therapy, 121 (27%) were indicated for antiviral
treatment but not treated while the remaining 160
(36%) were not indicated for treatment. As hepatitis B
virus (HBV) DNA and liver biopsy were not routine
tests, we arbitrarily deﬁned patients who had evidence
of liver cirrhosis and those who had elevated ALT were
indicated for antiviral treatment. This would be an
underestimate as a signiﬁcant proportion of patients
who had high normal ALT might already have ad-
vanced liver ﬁbrosis, particularly the older patients with
elevated HBV DNA [2,3]. The exact reasons why some
patients did not receive antiviral treatment were not ex-
plored in this audit. One obvious reason was that a sig-
niﬁcant proportion of untreated patients did not meet
the criteria for reimbursement and could not aﬀord the
high cost of the antiviral medications.
Overall, only 27 of 444 (6.1%) patients in our clinic
were treated under the hospital reimbursement scheme.
One hundred and thirty-six (83%) of the 163 treated pa-
tients were purchasing their antiviral medications with-
out reimbursement. These numbers again reﬂect the
inadequacy of the highly restricted reimbursement pol-
icy in force in Hong Kong. In our previously conducted
cross-sectional studies including over 1500 chronic hep-
atitis B patients, approximately 3.5% of hepatitis B e
antigen (HBeAg)-positive patients and 2% of HBeAg-
negative patients had ALT levels higher than 5 times
ULN [2,3]. The prevalence of clinical liver cirrhosis
was approximately 16% among HBeAg-negative pa-
tients in our clinic, and the prevalence of decompensated
cirrhosis was expected to be lower [4]. In other words,
the number of patients eligible for reimbursement under
the current policy would only be a minority of all those
who should be indicated for antiviral treatment accord-
ing to the Asian-Paciﬁc recommendations [5].
The most commonly used antiviral medication was
entecavir (Fig. 1). Seventy-two (44% of the treated) pa-
tients were on entecavir but only one of them was reim-
bursed. This was partly related to a very recent change
in reimbursement policy and the restricted criteria for
reimbursement. Adefovir was used in 32 (20% of the
treated) patients and 7 of them were reimbursed. Thir-
teen of the 32 patients on adefovir were using combina-
tion treatment with lamivudine or entecavir for
lamivudine resistance. Although adefovir was used pri-
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